Malignant Transformation of Mastocytoma Developed on Skin Mastocytosis Into Cutaneous Mast Cell Sarcoma

被引:24
作者
Auquit-Auckbur, Isabelle [1 ]
Lazar, Calin [5 ]
Deneuve, Sophie [6 ]
Guillemet, Cecile [3 ]
Cordel, Nadege [7 ]
Blanchard, France [2 ]
Joly, Pascal [4 ,7 ]
Courville, Philippe [2 ]
机构
[1] Rouen Univ Hosp, Dept Plast Surg, Rouen, France
[2] Rouen Univ Hosp, Dept Pathol, Rouen, France
[3] Rouen Univ Hosp, Becquerel Inst, Dept Oncol, Rouen, France
[4] Rouen Univ Hosp, Dept Dermatol, Rouen, France
[5] Meulan Reg Hosp, Dept Plast Surg Aesthet & Reconstruct Surg, F-78250 Meulan, France
[6] Inst Gustave Roussy, Dept ENT & Cervicofacial Surg, Villejuif, France
[7] Pointe Pitre Univ Hosp, Dept Dermatol, Pointe A Pitre, Guadeloupe, France
关键词
c-Kit; CD117; imatinib; mastocytosis; mast cell sarcoma; radiotherapy; surgery; INHIBITS PROLIFERATION; TARGETED THERAPY; IMATINIB;
D O I
10.1097/PAS.0b013e31824c0d92
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Mastocytosis is a group of disorders characterized by abnormal mast cell proliferation, involving the skin in 80% of cases. Cutaneous mastocytosis, which appears in childhood in 60% of cases, usually has a benign course with a gradually regressive evolution before puberty. Mast cell sarcomas, part of the systemic forms of mastocytosis, are very rare tumors characterized by a destructive growth of highly atypical mast cells, with secondary spread, poor prognosis, and low survival rates. We report the first known case of primary cutaneous mast cell sarcoma due to the transformation of a benign solitary mastocytoma in an adult suffering from an unregressive localized cutaneous mastocytosis. Histologic characteristics of the tumor, mutation analysis, and c-Kit expression were compared with available data. Wide surgical excision of the tumor followed by adjuvant local radiotherapy were performed, and for the first time the use of imatinib was attempted, as neoplastic mast cells expressed the CD117 marker. However, they failed to control the progression of sarcoma. To date, no treatment is known to be effective for this disease, which is associated with short-term survival of the patients.
引用
收藏
页码:779 / 782
页数:4
相关论文
共 22 条
[1]   Molecular diagnosis of mast cell disorders - A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology [J].
Akin, Cem .
JOURNAL OF MOLECULAR DIAGNOSTICS, 2006, 8 (04) :412-419
[2]   Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas [J].
Antonescu, Cristina R. .
MODERN PATHOLOGY, 2008, 21 :S31-S36
[3]   SOLITARY MASTOCYTOMA IN AN ADULT - TREATMENT BY EXCISION [J].
ASHINOFF, R ;
SOTER, NA ;
FREEDBERG, IM .
JOURNAL OF DERMATOLOGIC SURGERY AND ONCOLOGY, 1993, 19 (05) :487-488
[4]   URTICARIA-PIGMENTOSA - A REVIEW OF 67 PEDIATRIC CASES [J].
AZANA, JM ;
TORRELO, A ;
MEDIERO, IG ;
ZAMBRANO, A .
PEDIATRIC DERMATOLOGY, 1994, 11 (02) :102-106
[5]   Mast-cell sarcoma of the tibia [J].
Brcic, Luka ;
Vuletic, Lovorka Batelja ;
Stepan, Jasminka ;
Bonevski, Aleksandra ;
Jakovljevic, Gordana ;
Gasparov, Slavko ;
Marjanovic, Ksenija ;
Seiwerth, Sven .
JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (04) :424-425
[6]   Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma [J].
Chott, A ;
Guenther, P ;
Huebner, A ;
Selzer, E ;
Parwaresch, RM ;
Horny, HP ;
Valent, P .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (07) :1013-1019
[7]   Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group [J].
Debiec-Rychter, M ;
Dumez, H ;
Judson, I ;
Wasag, B ;
Verweij, J ;
Brown, M ;
Dimitrijevic, S ;
Sciot, R ;
Stul, M ;
Vranck, H ;
Scurr, M ;
Hagemeijer, A ;
Van Glabbeke, M ;
van Oosterom, AT .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (05) :689-695
[8]  
Dirnhofer St, 2006, Ther Umsch, V63, P273, DOI 10.1024/0040-5930.63.4.273
[9]   Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell Factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis [J].
González, I ;
Andreu, EJ ;
Panizo, A ;
Inogés, S ;
Fontalba, A ;
Fernández-Luna, JL ;
Gaboli, M ;
Sierrasesúmaga, L ;
Martín-Algarra, S ;
Pardo, J ;
Prósper, F ;
de Alava, E .
CLINICAL CANCER RESEARCH, 2004, 10 (02) :751-761
[10]   The Role of High-Dose Imatinib in the Management of Patients With Gastrointestinal Stromal Tumor [J].
Gronchi, Alessandro ;
Blay, Jean-Yves ;
Trent, Jonathan C. .
CANCER, 2010, 116 (08) :1847-1858